Alpha-synuclein gene duplication: Marked intrafamilial variability in two novel pedigrees
ABSTRACT Background Multiplications of the SNCA gene that encodes alpha‐synuclein are a rare cause of autosomal dominant Parkinson's disease (PD). Methods Here, we describe 2 novel families in which there is autosomal dominant PD associated with SNCA duplication, and we compare the clinical fea...
Saved in:
Published in: | Movement disorders Vol. 28; no. 6; pp. 813 - 817 |
---|---|
Main Authors: | , , , , , , , , , |
Format: | Journal Article |
Language: | English |
Published: |
United States
Blackwell Publishing Ltd
01-06-2013
Wiley Subscription Services, Inc |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | ABSTRACT
Background
Multiplications of the SNCA gene that encodes alpha‐synuclein are a rare cause of autosomal dominant Parkinson's disease (PD).
Methods
Here, we describe 2 novel families in which there is autosomal dominant PD associated with SNCA duplication, and we compare the clinical features of all known patients carrying 3 or 4 SNCA copies.
Results
Affected members in family A presented with early onset PD that was variably associated with nonmotor features, such as dysautonomia, cognitive deficits, and psychiatric disturbances. In family B, the clinical presentation ranged from early onset PD‐dementia with psychiatric disturbances to late onset PD with mild cognitive impairment.
Conclusions
The presence of 4 SNCA copies is associated with a rich phenotype, characterized by earlier onset of motor and nonmotor features compared with patients who bear 3 SNCA copies. The clinical spectrum associated with SNCA duplications is wide, even within a single family, suggesting a role for as yet unidentified genetic or environmental modifiers. © 2013 Movement Disorder Society |
---|---|
Bibliography: | istex:1F3379552CE68FAE894F37B7BFCD53303E26F9EF ark:/67375/WNG-NV0P4XRM-1 ArticleID:MDS25518 Full financial disclosures and author roles may be found in the online version of this article. Nothing to report. The research leading to these results has received funding from the Italian Ministry of Health (Ricerca Corrente 2012, Ricerca Finalizzata Malattie Rare 2008) and from the European Community's Seventh Framework Programme (FP7/2007–2013) under grant agreement no. 241791 (European Project on Mendelian Forms of Parkinson's Disease [MEFOPA]). Relevant conflicts of interest/financial disclosures These authors contributed equally this work. Funding agencies ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 0885-3185 1531-8257 |
DOI: | 10.1002/mds.25518 |